« Return to News | R&D Trends | Drug Sponsors

Jubilant, Janssen collaborate on neuroscience development

Thursday, June 30, 2011 01:28 PM

A Jubilant Life Sciences subsidiary has formed an alliance to deliver pre-clinical candidates in the neuroscience field to Belgium’s Janssen Pharmaceutica, according to PharmaTimes.

Bedminster, N.J.-based Jubilant Discovery Services is working with Johnson & Johnson’s Janssen division for an initial three-year period. The alliance will focus on multiple drug targets in neuroscience.

Janssen will transfer certain ongoing efforts on selected drug discovery targets to Jubilant, while Jubilant will contribute research services and deliver pre-clinical candidates to Janssen for possible further development and commercialization.

Jubilant may be eligible for milestones and royalties should Janssen successfully develop and commercialize drug candidates covered by the alliance, Jubilant noted.

The collaboration will draw on Jubilant’s global research network, including a new research facility in the U.S. focused on neuroscience, as well as the company’s India-based research centers.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.